Muhammad Kashif, MD
Nephrology · Pine Bluff, ARNPI 1194719203
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $507 and has fallen 99.7% since, to $2 in 2025. That places this record below the midpoint for nephrology clinicians in AR, where the typical reported total is $925.
Across 53 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$271
- Fresenius USA Marketing, Inc.$253
- Akebia Therapeutics Inc$165
- Vifor Pharma, Inc.$131
- Amgen$91
- Genentech USA, Inc.$75
- plus $186 from 6 others
Across 78 payments — averaging $2042.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$159K
What the payments were for
- Food & beverage$1,12996%
- Education$434%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $271 |
| Fresenius USA Marketing, Inc. | 12 | $253 |
| Akebia Therapeutics Inc | 9 | $165 |
| Vifor Pharma, Inc. | 3 | $131 |
| Amgen(2 entities) | 5 | $91 |
| Genentech USA, Inc. | 1 | $75 |
| Aurinia Pharma U.S., Inc. | 4 | $72 |
| GSK | 3 | $38 |
| Bayer | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,171 in reported general payments places this provider in the 50th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 61 | $121,885 |
| Sevelamer Carbonate | 154 | $28,570 |
| RenvelaSevelamer Carbonate | 13 | $18,437 |
| AuryxiaFerric Citrate | 14 | $17,423 |
| Paricalcitol | 134 | $16,164 |
| FarxigaDapagliflozin Propanediol | 22 | $15,846 |
| Calcitriol | 674 | $12,793 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 30 | $9,404 |
| ProsolParenteral Amino Acid 20% No.1 | 42 | $7,072 |
| Allopurinol | 853 | $5,215 |
| Cinacalcet Hcl | 29 | $1,870 |
| Hydralazine Hcl | 152 | $1,148 |
| Calcium Acetate | 19 | $1,082 |
| Nifedipine ErNifedipine | 91 | $845 |
| Potassium Chloride | 65 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $253 | $121,88561 claims |
| Akebia Therapeutics IncAuryxia | $165 | $17,42314 claims |
| AstraZenecaFarxiga | $271 | $15,84622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 85 nephrology providers in Arkansas.
Other nephrology in Pine Bluff
- Brandi WrightPine Bluff$2K
- James CampbellPine Bluff$2K
- Syed Sheheryar Ahmed ShahPine Bluff$2K
- Drew HeipleRussellville$236K
- Luis JuncosLittle Rock$66K
- John HeifnerLittle Rock$45K
- Shaker QaqishNorth Little Rock$16K
- Michael GerschHot Springs$10K
- Mary Shaver-LewisConway$10K
- Clinton EdwardsJonesboro$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.